Application Detail
Description of Medical Service
Axicabtagene ciloleucel is a CAR T-cell product produced using a patient’s own T-cells, making the product unique to each patient. A patient’s T-cells are collected via a process called leukapheresis. The T-cells are genetically modified in a lab to express an anti-CD19 chimeric antigen receptor (CAR) which targets the lymphoma B-cells. Following modification and subsequent proliferation, the T-cells are infused back into the patient where they target and kill the lymphoma B-cells.Description of Medical Condition
Large B-cell lymphoma (LBCL) is a collection of entities that are subtypes of non-Hodgkin’s lymphoma. LBCL accounts for roughly one third of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease or both.Reason for Application
Highly Specialised Therapy - National Health Reform AgreementMedical Service Type
Therapeutic technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Form
Application Form (PDF 1204 KB)Application Form (Word 415 KB)
Consultation Survey
Consultation Survey (PDF 658 KB)Consultation Survey (Word 27 KB)
PASC Consultation
Expedited – Bypassing PASC
MSAC Consultation
MSAC consultation input must be received by no later than Friday, 10 February 2023 for it to be considered by MSAC at its March 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process